Paradigm Biopharmaceuticals Limited operates as a biopharmaceutical company. The Company develops PPS drug to treat respiratory diseases such as allergic asthma, allergic rhinitis, and chronic obstructive pulmonary. Paradigm Biopharmaceuticals offers its services in Australia.

Change in substantial holding

Application for quotation of securities - PAR

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Paradigm Biopharmaceuticals (PAR AU)

Change in substantial holding

Application for quotation of securities - PAR

Quarterly Activities/Appendix 4C Cash Flow Report

Notification of cessation of securities - PAR

Type D Response Submitted and Received by the US FDA

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)